The gastrointestinal effects typically emerge within the first few weeks of treatment and may evolve as the body adapts to the medication
Signs of dehydration, including dizziness, very dark urine, weakness, dry mouth, or fainting
Some of the best strategies include changing your eating habits, hydrating wisely, staying upright after eating, using anti-nausea remedies, and following a titration schedule
Key Products: Pemvidutide, balanced 1:1 dual GLP-1/glucagon receptor agonist, designed to drive both appetite suppression (GLP-1) and direct hepatic fat oxidation (glucagon)
Future GLP-1 trends: new drugs and therapies on the horizon The future of weight management may soon involve more than current GLP-1s: Amylin mimetics: These compounds mimic another satiety hormone and may complement GLP-1s. Mazdutide: A dual glucagon/GLP-1 agonist showing strong Phase 3 results and promising greater weight loss. Oral GLP-1s: Pills in development could improve convenience. Muscle-preserving combinations: Researchers are exploring co-therapies to prevent loss of lean mass during weight loss. Providers should prepare for a rapidly evolving landscape and educate patients about upcoming options. Key takeaways on GLP-1 trends for providers and patients Efficacy varies across drugs and doses
In addition, the fatty acid fraction can be reversibly and non-covalently bound to human serum albumin (HSA), slowing down the renal clearance